Troy A. Ignelzi - 15 Nov 2022 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Financial Officer
Signature: /s/ Troy Ignelzi
Issuer symbol: N/A
Transactions as of: 15 Nov 2022
Net transactions value: -$3,574,725
Form type: 4
Filing time: 17 Nov 2022, 16:08:58 UTC
Previous filing: 04 Oct 2022
Next filing: 19 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$151,800	+16,500	+165%	$9.20^*	26,470	15 Nov 2022	Direct
transaction	KRTX	Common Stock	Sale	$3,726,525	-16,500	-62%	$225.85	9,970	15 Nov 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-16,500	-12%	$0.000000	121,612	15 Nov 2022	Common Stock	16,500	$9.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 1, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.74 to $225.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.